ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadju

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05633654

Clinical trials study type

Oncology - Breast

Clinical trials trial status

Open to Accrual

IRB number

2094429

Principal investigator

Robert Donegan, MD

Clinical trials study number

ASCENT-05 (G2309)

Clinical trials title (full)

ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy